COMMUNIQUÉS West-GlobeNewswire

ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy

07/06/2017 - 13:00

- OBE2109 is a GnRH receptor antagonist currently in development as both a stand-alone treatment and with add-back therapy designed to address the needs of endometriosis and uterine fibroid patients - Geneva, [...]

Midatech signs global license agreement to investigate panobinostat for treatment of brain cancers

07/06/2017 - 13:00

7 June 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") Midatech signs global license agreement to investigate panobinostat for treatment of brain cancers Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the [...]

Biocartis Group NV: MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

07/06/2017 - 07:00

PRESS RELEASE: 7 June 2017, 07:00 CEST MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer Partnership aimed at the development of molecular diagnostic assays on Biocartis' fully [...]

Solon Eiendom ASA - Primary insider notification

06/06/2017 - 22:01

SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, 6 June 2017) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company Hortulan [...]

ProMIS(TM) Neurosciences Appoints William C. Mobley to Scientific Advisory Board

06/06/2017 - 18:42

TORONTO and CAMBRIDGE, Mass., June 06, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX:PMN), a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative [...]

Essilor : Nombre total de droits de vote et d'actions composant le capital social au 31 mai 2017

06/06/2017 - 18:00

Nombre total de droits de vote et d'actions composant le capital social au 31 mai 2017 (Article L.233-8 II du Code de Commerce et les articles 221-1 et 223-16 du Règlement Général de l'AMF) Charenton-le-Pont, France (le [...]

Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2017

06/06/2017 - 18:00

Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2017 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]

Ossur Hf : Transactions in relation to share buyback program

06/06/2017 - 18:00

Announcement from Össur hf. No. 43/2017 Reykjavík, 05 June 2017 On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is to [...]

Issuance of new shares to the Finnish Innovation Fund Sitra pursuant to the financing arrangement announced on 21 July 2016

06/06/2017 - 18:00

Company announcement, Helsinki, 6 June 2017 at 7:00 pm Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), a medical technology company developing and marketing pioneering navigated non-invasive brain [...]

MITHRA SIGNS EXCLUSIVE AGREEMENT FOR TIBELIA® IN CANADA

06/06/2017 - 17:45

PRESS RELEASE Mithra signs Exclusive agreement for Tibelia® in Canada Tibelia® would be the first tibolone-based Hormone Therapy product available in Canada Marketing authorization process is ongoing Tibelia® already [...]

Refixia® (nonacog beta pegol; N9-GP) approved in the EU

06/06/2017 - 16:55

Company Announcement No 42/2017 This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely [...]

Medtronic Announces Scientific Data Presentations at the American Diabetes Association 77th Meeting

06/06/2017 - 16:30

Medtronic Will Host a Webcast of Its Diabetes Group Analyst and Investor Briefing on Saturday, June 10 from 2 - 4 p.m. PDT DUBLIN - June 6, 2017 - Medtronic (NYSE:MDT), the global leader in medical technology, today [...]

Medtronic SureTune(TM)3 Receives Health Canada Licence for Deep Brain Stimulation Therapy

06/06/2017 - 16:00

DUBLIN - June 6, 2017 - Medtronic plc (NYSE: MDT) today announced it has received a Health Canada licence for SureTune(TM)3 software for deep brain stimulation (DBS). The latest innovations in the SureTune technology [...]

AbCellera Announces an Antibody Discovery Program in Influenza Vaccine Research

06/06/2017 - 15:00

AbCellera announces a project with Sanofi Pasteur to apply its human antibody discovery and immune profiling technology for the research and development of next-generation influenza vaccines. VANCOUVER, British Columbia [...]

Annual General Meeting held

06/06/2017 - 14:37

Navamedic ASA has today, 6 June 2017, held an annual general meeting. All resolutions were made in accordance with the board's/nomination committee's proposals. The minutes from the general meeting is attached hereto [...]

Novo Nordisk A/S - Share repurchase programme

06/06/2017 - 14:25

Bagsværd, Denmark, 06 June 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]

Helsinn Group signs Exclusive Agreement with Purdue Pharma (Canada) for the Distribution and Licensing Rights of Aloxi® (palonosetron hydrochloride) in Canada

06/06/2017 - 13:30

Helsinn Group signs Exclusive Agreement with Purdue Pharma (Canada) for the Distribution and Licensing Rights of Aloxi ® (palonosetron hydrochloride) in Canada Lugano, Switzerland and Pickering, Canada, June 6, 2017 - [...]

Verona Pharma plc : Holding(s) in Company

06/06/2017 - 13:29

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Verona Pharma Plc 2 Reason for the notification (please [...]

uniQure Announces Appointment of Steven L. Zelenkofske as Chief Medical Officer

06/06/2017 - 13:00

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 06, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq:QURE), a leader in human gene therapy, today announced the appointment of Steven L. Zelenkofske, D.O., as Chief [...]